Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

被引：0
作者：
Gonzalez-Cao, Maria
de las Casas, Clara Mayo
Oramas, Juana
Berciano-Guerrero, Miguel-Angel
De la Cruz, Luis
Cerezuela-Fuentes, Pablo
Arance, Ana Maria
Munoz-Couselo, Eva
Espinosa, Enrique
Puertolas, Teresa
Beveridge, Robert Diaz
Ochenduszko, Sebastian
Silva, Maria Jose Villanueva
Basterretxea, Laura
Bellido, Lorena
Rodriguez-Abreu, Delvys
Drozdowskyj, Ana
Vila, Miguel Angel Molina
Lopez-Martin, Jose Antonio
Berrocal, Alfonso
机构：
[1] Inst Oncol Dr Rosell, Barcelona, Spain
[2] Pangaea Oncol, Barcelona, Spain
[3] Hosp Univ Canarias, Tenerife, Spain
[4] HURyVV Hosp Univ Reg & Virgen Victoria Malaga, Unidad Intercentros Oncol, IBIMA Inst Invest Biomed Malaga, Malaga, Spain
[5] Hosp Univ Virgen Macarena, Seville, Spain
[6] Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain
[7] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[8] Vall dHebron Inst Oncol, Vall dHebron Hosp, Barcelona, Spain
[9] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
[10] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
[11] Hosp Univ & Politec La Fe, Valencia, Spain
[12] Hosp Univ Dr Peset, Valencia, Spain
[13] Complexo Hosp Univ Vigo, Vigo, Spain
[14] Hosp Univ Donostia, San Sebastian, Spain
[15] Hosp Univ Salamanca, Salamanca, Spain
[16] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain
[17] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Dept Oncol, Barcelona, Spain
[18] Hosp 12 Octubre, Madrid, Spain
[19] Hosp Gen Univ Valencia, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9528
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
    de la Cruz-Merino, Luis
    Di Guardo, Lorenza
    Grob, Jean-Jacques
    Venosa, Alfredo
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    Ascierto, Paolo A.
    Evans, Jeffrey T. R.
    Gomez-Escobar, Antonio
    Barteselli, Giulio
    Eng, Susan
    Hsu, Jessie J.
    Uyei, Anne
    Dreno, Brigitte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [22] Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
    Luis de la Cruz-Merino
    Lorenza Di Guardo
    Jean-Jacques Grob
    Alfredo Venosa
    James Larkin
    Grant A. McArthur
    Antoni Ribas
    Paolo A. Ascierto
    Jeffrey T. R. Evans
    Antonio Gomez-Escobar
    Giulio Barteselli
    Susan Eng
    Jessie J. Hsu
    Anne Uyei
    Brigitte Dréno
    Journal of Translational Medicine, 15
  • [23] Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
    Ascierto, Paolo. A.
    Cioli, Eleonora
    Chiarion-Sileni, Vanna
    Quaglino, Pietro
    Spagnolo, Francesco
    Guidoboni, Massimo
    Del Vecchio, Michele
    Peris, Ketty
    Queirolo, Paola
    Fioretto, Luisa
    Caraco, Corrado
    Paone, Miriam
    Sorrentino, Antonio
    Capone, Mariaelena
    Giannarelli, Diana
    Ferrara, Gerardo
    Massi, Daniela
    Trojaniello, Claudia
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial
    Algazi, Alain P.
    Othus, Megan
    Daud, Adil, I
    Lo, Roger S.
    Mehnert, Janice M.
    Thach-Giao Truong
    Conry, Robert
    Kendra, Kari
    Doolittle, Gary C.
    Clark, Joseph, I
    Messino, Michael J.
    Moore, Dennis F., Jr.
    Lao, Christopher
    Faller, Bryan A.
    Govindarajan, Rangaswamy
    Harker-Murray, Amy
    Dreisbach, Luke
    Moon, James
    Grossmann, Kenneth F.
    Ribas, Antoni
    NATURE MEDICINE, 2020, 26 (10) : 1564 - +
  • [25] A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
    Simeone, Ester
    Scognamiglio, Giosue
    Capone, Mariaelena
    Giannarelli, Diana
    Grimaldi, Antonio M.
    Mallardo, Domenico
    Madonna, Gabriele
    Curvietto, Marcello
    Esposito, Assunta
    Sandomenico, Fabio
    Sabbatino, Francesco
    Bayless, Nicholas L.
    Warren, Sarah
    Ong, SuFey
    Botti, Gerardo
    Flaherty, Keith T.
    Ferrone, Soldano
    Ascierto, Paolo A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [26] Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
    Ribas, Antoni
    Gonzalez, Rene
    Pavlick, Anna
    Hamid, Omid
    Gajewski, Thomas F.
    Daud, Adil
    Flaherty, Lawrence
    Logan, Theodore
    Chmielowski, Bartosz
    Lewis, Karl
    Kee, Damien
    Boasberg, Peter
    Yin, Ming
    Chan, Iris
    Musib, Luna
    Choong, Nicholas
    Puzanov, Igor
    McArthur, Grant A.
    LANCET ONCOLOGY, 2014, 15 (09) : 954 - 965
  • [27] A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
    Ester Simeone
    Giosuè Scognamiglio
    Mariaelena Capone
    Diana Giannarelli
    Antonio M. Grimaldi
    Domenico Mallardo
    Gabriele Madonna
    Marcello Curvietto
    Assunta Esposito
    Fabio Sandomenico
    Francesco Sabbatino
    Nicholas L. Bayless
    Sarah Warren
    SuFey Ong
    Gerardo Botti
    Keith T. Flaherty
    Soldano Ferrone
    Paolo A. Ascierto
    Journal of Translational Medicine, 19
  • [28] Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
    Hong, David S.
    Morris, Van Karlyle
    El Osta, Badi Edmond
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Kee, Bryan K.
    Tsimberidou, Apostolia Maria
    Zinner, Ralph
    Fogelman, David R.
    Bellido, Jorge
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma.
    Daud, Adil
    Pavlick, Anna C.
    Ribas, Antoni
    Gonzalez, Rene
    Lewis, Karl D.
    Hamid, Omid
    Gajewski, Thomas
    Puzanov, Igor
    Hsu, Jessie J.
    Koralek, Daniel O.
    Choong, Nicholas W.
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results
    Petrella, Teresa M.
    Mihalcioiu, Catalin Liviu Dragos
    Nessim, Carolyn
    Spatz, Alan
    Watson, Ian
    Wright, Frances Catriona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345